Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Those who are known to have an allergic reaction to any component of the study drug；

Local treatments such as radiotherapy, radiofrequency ablation, intervention, etc or surgical procedures (excluding prior diagnostic biopsy) in the 28 days before first administration；

Known brain metastasis and/or leptomeningeal disease；

People with complete intestinal obstruction and incomplete intestinal obstruction requiring treatment. However, patients whose obstruction is relieved by fistula or stent placement can be included in the group;

Active severe clinical infection (\> Grade 2, NCI-CTCAE version 5.0), including active tuberculosis；

Uncontrolled diabetes (fasting blood glucose ≥10 mmol/L), severe lung disease (such as acute lung disease, pulmonary fibrosis that affects lung function, interstitial lung disease. Except for radiation pneumonia that has recovered), liver failure；

Clinically significant cardiovascular diseases, such as heart failure (NYHAⅢ-Ⅳ), uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, hypertension (systolic blood pressure\>150mmHg and/or diastolic blood pressure\>100mmHg), echocardiography The figure shows the ejection fraction \<50%, the history of myocardial infarction within the past two years；

Renal replacement therapy；

\> Grade 1 Peripheral Nerve Disorder (NCI-CTCAE Version 5.0)；

History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation；

Previous malignancy other than CRC in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix；

HIV infection, hepatitis B surface antigen positive (and peripheral blood hepatitis B virus deoxynucleotide HBV DNA ≥ 1×10ˆ4 copy number/ml or ≥ 2000 IU/ml), hepatitis C virus antibody positive (and peripheral blood hepatitis C virus nucleotide HCV RNA≥ 1×10ˆ3 copies/ml or ≥ 200 IU/ml)；

Patients with coagulation dysfunction, meet any of the following conditions: prothrombin time (PT) ≥ 1.5 ULN， thrombin time (TT) ≥ 1.5 ULN,activated partial thromboplastin time (APTT) ≥ 1.5 ULN;

Previously treatment with VEGF pathway targeted therapy and EGFR monoclonal antibody；

Past treatment history:

1. Receiving other anti-tumor treatments (including anti-tumor treatments with traditional Chinese medicines, such as Aidi injection, Kanglaite injection, Kangai injection, cininobufosin, brucea javanica oil, etc.) within 4 weeks before the first administration of the study ；

2. Long-term systemic immunotherapy, or hormone therapy for anti-tumor purposes (physiological replacement therapy, except for those with hypothyroidism who take thyroxine);

3. Have received G-CSF, GM-CSF, whole blood or blood component transfusions within 4 weeks before the first medication of the study;

4. Have received other experimental drugs or interventional clinical studies within 4 weeks before the first medication of the study；

Pregnancy (confirmed by blood pregnancy test) or lactation；

There is currently alcohol or drug dependence；

There is a clear neurological disease or mental illness that has not been cured, including epilepsy, dementia, schizophrenia, etc；

Adverse events of previous treatment (except for hair loss) did not return to grade 1 or below (NCI-CTCAE version 5.0)；

The researcher believes that the patient has other factors that affect the efficacy or safety evaluation of this study

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

What this study is about

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

What this study is about